Lv5
901 积分 2021-02-20 加入
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
10天前
已完结
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
19天前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
19天前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
19天前
已完结
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis
29天前
已完结
Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys
29天前
已完结
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis
29天前
已完结
LB1008 KLK5/7 targeting antibody, TRIV-509, ameliorates barrier dysfunction, inflammation and itch in atopic dermatitis models
29天前
已完结
High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo
1个月前
已完结
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
1个月前
已完结
皖公网安备34019202002308
